Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355210 | 0.82 | GAA (0.42) | CYP2C19CYP1A2ALDH1A1MAPTALOX5 | |
| SCHEMBL1875535 | 0.73 | KMT2A (0.35) | CYP2C19CYP1A2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5025929 | 0.70 | SMN1; SMN2 (0.41) | ALDH1A1MAPTSMN1; SMN2ALOX5MEN1 | |
| SCHEMBL3120886 | 0.67 | L3MBTL1 (0.45) | ALDH1A1MAPTSMN1; SMN2ALOX5MEN1 | |
| SCHEMBL4296608 | 0.67 | CYP2C19 (0.41) | CYP2C19CYP3A4CYP1A2ALDH1A1MAPT | |
| SCHEMBL8509315 | 0.66 | HDAC4 (0.57) | CYP2C19CYP3A4CYP1A2MAPTCYP2D6 | |
| SCHEMBL9198007 | 0.64 | ALDH1A1 (0.52) | CYP2C19CYP3A4CYP1A2ALDH1A1MAPT | |
| SCHEMBL8812813 | 0.64 | L3MBTL1 (0.39) | CYP2C19CYP3A4CYP1A2ALDH1A1MAPT | |
| SCHEMBL8749884 | 0.64 | GAA (0.36) | ALDH1A1MAPTSMN1; SMN2ALOX5MEN1 | |
| SCHEMBL601390 | 0.62 | MAPT (0.41) | CYP2C19CYP3A4CYP1A2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | FORSCHUNGSZENTRUM BORSTEL (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | CTSF, ADAM17, ADAM10 | CYP2C19 786/4885CYP3A4 283/4885CYP1A2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.